Patients with heart failure who describe themselves as being socially isolated have an increased risk of death and also have an increased use of healthcare resources, according to new research published in the Journal of the American Heart Association on May 23.

Senior citizens who reported exercising at least four times a week throughout their lives showed decreased age-related arterial stiffness when compared to more sedentary individuals, according to a study published May 20 in the Journal of Physiology.

The FDA has issued a Class I recall of the HeartMate 3 Left Ventricular Assist System (Abbott) because a malfunction in the device’s outflow graft assembly could lead to graft occlusion, possibly reducing or stopping blood flow.

Two late-breaking clinical trials presented May 23 at EuroPCR in London demonstrated the ability of renal denervation to significantly lower patients’ blood pressures, regardless of whether they were taking antihypertensive medications.

REDWOOD CITY, Calif., May 23, 2018 - Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the Company received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its next generation Pantheris® Lumivascular atherectomy system, the first-ever image-guided atherectomy device for the treatment of peripheral artery disease.

The FlowTriever System has become the first thrombectomy device designed to treat pulmonary embolism (PE) to be cleared by the FDA, Inari Medical announced in a May 21 press release.

At EuroPCR in Paris, investigators of the controversial ORBITA trial presented two previously unreported benefits of percutaneous coronary intervention (PCI) for the study population.

Two hospitals in East Africa have announced participation in the American College of Cardiology’s CathPCI registry, which aims to assess treatments and outcomes related to cardiac catheterization and percutaneous coronary interventions (PCIs).